Another interesting field of research is the study of drug combinations, to evaluate the effect of combining IDH-inhibitors with chemoradiation treatments in patients with WHO grade 3 or 4 IDH-mutant gliomas. The gene discussed is IDH2; the disease is central nervous system cancer.